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S258 Poster Session Iprednisone. Patients werematched at 4 (9%), 5 (67%) or 6 (24%) of 6
loci (high resolution at DRB1). Incidence of acute GVHD grade II-
IV was 36% and grade III-IV was 21%. Chronic GVHDwas absent
in 88% of evaluable patients, but limited in 12% with none having
extensive cGVHD. Please see Table for survival data.
Conclusion: Cord blood transplant offers a viable alternative to
bone marrow as a source of hematopoietic stem cells for transplan-
tation. Over the 16 years that cord blood has been used at our insti-
tution, significant improvement in survival was appreciated over the
latter half of that period. This is most likely do to a number of factors
including transplant center experience, improvements in supportive
care, more cord units available to select from and better appreciation
of factors (such asminimumnumber of cells needed for engraftment)
important in choosing the optimal graft. These results compare
favorably with matched bone marrow transplant controls.285
DOES EARLY INITIATION OF THERAPEUTIC PLASMA EXCHANGE AFFECT
OUTCOME IN PEDIATRIC STEM CELL TRANSPLANT-ASSOCIATED
THROMBOTIC MICROANGIOPATHY?
Jodele, S.1, Laskin, B.L.2, Pinkard, S.L.3, Carey, P.M.3, Goebel, J.2,
Davies, S.M.1 1Cincinnati Children’s Hospital Medical Center, Cincin-
nati, OH; 2Cincinnati Children’s Hospital Medical Center, Cincinnati,
OH; 3University of Cincinnati, Cincinnati, OH
Stem cell transplant (SCT)-associated thrombotic microangiop-
athy (TMA) is a serious complication leading to acute and chronic
kidney injury, often with high mortality. The diagnosis of TMA is
challenging, and its unclear pathogenesis limits development of op-
timal therapies. We retrospectively reviewed 10 patients with TMA
receiving therapeutic plasma exchange (TPE). Criteria for TMA
diagnosis included microangiopathy (anemia, thrombocytopenia,
elevated LDH, decreased haptoglobin, presence of schistocytes, neg-
ative DAT) and impaired renal function.
TMAwas diagnosed within 100 days post-SCT in 9 of 10 patients.
Three of 10 patients had renal biopsy-proven TMA. These biopsies,
even though challenging in SCT, aided in the decision to institute
therapy. Direct sequence analysis of the complement genes CH1,
CFH, MCP, CFB, and CFR5 was performed in 4 patients and was
normal. However, 2 of these 4 patients had detectable CFH autoan-
tibodies. IL-8 and IL-6 levels were elevated in the 4 patients tested
for plasma cytokines. Seven patients were on renal replacement ther-
apy (RRT) and 6 on ventilator support during TMA. Eight patients
received 2-4 weekly rituximab doses without full response and pro-
ceeded to TPE, while 2 started rituximab and TPE concomitantly.
Single volume daily TPE was initiated 4-73 days after TMA diagno-
sis, continued until resolution of microangiopathic anemia, and then
tapered off after a median of 35 TPE sessions (range 17-79).
Even though 9/10 patients showed laboratory resolution of micro-
angiopathic anemia duringTPE, only 5 patients survived at amedian
of 525 days post-SCT (range 217-777 days). The 5 survivors started
TPE a median of 17 days (range 4-25 days) after TMA diagnosis,
while the 5 patients who died startedTPE amedian of 32 days (range
17-73 days) after TMA diagnosis. Notably, 3 of the 5 survivors had
multiorgan failure at TMA diagnosis and completely recovered
with early institution of TPE. All survivors eventually had normal
creatinine off RRT. Conversely, the 5 patients who had late institu-
tion of TPE developed chronic renal dysfunction (n 5 1) or end-
stage renal disease (n 5 4) and died at a median of 334 days post
SCT (range 151-631 days). Our data suggest the survival benefit of
early TMA diagnosis and therapy with TPE and rituximab which
may work by removing CFH autoantibodies or endothelium damag-
ing cytokines. Larger, prospective studies are required to evaluate
the benefit of these therapies in TMA.286
IV BUSULFAN ADMINISTERED q12 VS q6 HRS DURING CONDITIONING
OF PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT (AlloSCT)
RECIPIENTS HAS COMPARABLE PHARMACOKINETICS AND SIGNIFICANT
REDUCTION IN NURSING/PHARMACIST COSTS
LeGall, J.1, Milone, M.C.2, Waxman, I.M.1, Shaw, L.M.2,
Harrison, L.1, Duffy, D.1, Militano, O.1, Bhatia, M.1, Satwani, P.1,George, D.1, Garvin, J.H.1, Bradley, M.B.1, van de Ven, C.1,
Cairo, M.S.1,3,4 1Columbia University, New York, NY; 2University of
Pennsylvania, Philadelphia, PA; 3Columbia University, New York, NY;
4Columbia University, New York, NY
Inaccurate busulfan dosing during AlloSCT conditioning can re-
sult in graft failure or regimen-related toxicity (Andersson, BBMT,
2009). IV busulfan divided q6hrs is safe and effective in pediatric Al-
loSCT recipients at a dose of 4 mg/kg/day in patients# 4 yrs old and
at a dose of 3.2 mg/kg/day in patients . 4 yrs old (Wall et al, PBC,
2010). Less frequent dosing regimens are attractive for the possibility
of cost-effectiveness, but data is limited on comparing q12 to q6hr
infusions of IV busulfan in pediatric AlloSCT recipients.
We compared two cohorts of pediatric AlloSCT recipients receiv-
ing IV busulfan during conditioning. Cohort A received IV busulfan
q6hr x 16 doses and cohort B received IV busulfan q12hr x 8 doses
(age # 4yrs received 4.0 mg/kg/day; age . 4yrs received 3.2 mg/
kg/day). Busulfan levels were obtained at 1, 2, 3, 5, 6 and 8 hours after
the first dose and measured by gas chromatography – mass spectros-
copy (GC-MS) of heparinized plasma. The area under the curve
(AUC) was calculated by a 1-compartment modeling system. Pa-
tients in cohort B were monitored throughout AlloSCT for develop-
ment of moderate to severe hepatic veno-occlusive disease after
administration of IV busulfan. Finally, the savings of the q12 vs
q6hr dosing interval were estimated based on pharmacist/nurse sal-
ary and difference in the frequency of IV busulfan administration be-
tween the two cohorts.
In comparing cohort A (q6hr; n5 89; mean age 7.9 yrs) vs cohort
B (q12hr; n 5 38; mean age 8.7 yrs) there was no statistically signif-
icant difference in the volume of distribution (Vd(L)), half-life (min),
or clearance (Cl (ml/min/kg)).
Cohort A Cohort B
Q6 IV Bu Q12 IV Bu P valuesN 89 38 N/A
Age (yrs) 7.9 ± 6.9 8.7 ± 7.6 0.586
Weight (kg) 30.91 ± 24.6 28.2 ± 19 0.509
Vd (L) 20.6 ± 16.6 19.4 ± 13.7 0.676
Half-life (min) 132.0 ± 31.1 129.10 ± 38.15 0.678
Cl (ml/min/kg) 3.6 ± 0.9 4.0 ± 1.5 0.215
AUC (mmol *min/L) 1077 ± 352 1886 ± 420 <0.0001
Salary Cost ($USD/pt) $3,413 $1,733 N/AAs expected, there was a significant increase in the AUC in cohort B
(q12hr) vs cohort A (q6hr) (18866420 vs 10776352 mmol*min/L; p
\0.0001). Within cohort B (q12hr) there was only a 1/38 incidence
of moderate to severe VOD. Based on bedside RN salary of $40/hr
and pharmacist salary of $60/hr, a cost savings of $1,680/patient
was estimated with q12 vs q6hr IV busulfan dosing.
In summary, IV busulfan q12 vs q6hr dosing during conditioning
of pediatric AlloSCT recipients results in comparable busulfan Vd,
half-life, and Cl and, as expected, a significant increase in AUC. Fur-
thermore, IV q12hr busulfan results in a very low incidence of VOD
in pediatric AlloSCT recipients. Finally, a significant cost reduction
with decreased nursing and pharmacist costs can be achieved with
q12hr administration of IV busulfan.287
UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR
CHILDREN WITH b-THALASSEMIA MAJOR
Shah, S.A., Beniwal, S.K., Shah, K.M., Patel, K.A., Patel, K.M.,
Shah, P.M. Gujarat Cancer and Research Institute, Ahmedabad, Gujarat,
India
Background: Beta-thalassemia major, one of the most prevalent he-
moglobinopathies throughout the world, can be cured by allogeneic
stem cell transplantation. Many patients, however, lack a suitably
matched related sibling donor. Unrelated umbilical cord blood
can be used as an alternative stem cell source for these patients.
This report describes transplantation of 7 children with beta-thalas-
semia major using partially HLA-matched unrelated umbilical cord
blood.
Methods:Conditioning included busulfan 16 mg/kg (day -10 to -7),
cyclophosphamide 200 mg/kg(day -5 to -2), fludarabine 90 mg/kg
Poster Session I S259(day -13 to -11), and antithymocyte globulin (rabbit) 7.5 mg/kg(day
-3 to -1). The infused cell dose was 10.71  107/kg nucleated cells
(range from 6.5 to 17 107/kg nucleated cells. Age range from 1.5
year to 7 year. Weight range from10.5 t0 17 kg.
Failure of engraftment is a frequent complication following unre-
lated Umbilical Cord haematopoietic stem cell transplantation for
patients with thalassemia because of Limited dose of stem cells,
multiple transfusions and hypercellular marrow. We tried second
transplant with two unrelated cord blood units for primary graft fail-
ure after cord blood transplantation in one patient. The retransplant
recipients were preconditioned with i.v Cy 120 mg/kg (day -3 to -2) .
Results:Two patients engrafted promptly with 100% donor chime-
rism out of 6 children (33.33%). One child has 50 % donor chime-
rism on day 15. The absolute neutrophil count first exceeded 0.5 
109/l on day 17, and the patient became red cell- and platelet-
independent on days 34 and 49, respectively. All patients engrafted
at a median of 17 days (range 12–19). One patient is transfusion
free for 32 months while second patient is transfusion free for 13
months. There is no transplant related mortality (TRM).
The post transplant complications were mild hepatic veno-
occlusive disease, acute GVHD grade II, and CMV interstitial
pneumonia. The chronic GVHD was limited and could be con-
trolled by Methylprednisolone combined with Mycophenolate.
Conclusions: As there is no marrow donor registry in India, Umbil-
ical cord blood transplantation is a good alternative and is possible. It
should be considered for patients with beta-thalassemia major who
lack traditional bone marrow donors. Transplant should be done af-
ter 18months of age as earliest. Dose of stem cells is the most impor-
tant factor for engraftment. Results can be improved further with
more experience.288
ROLE OF GASTROINTESTINAL ENDOSCOPY IN ALTERING THE
MANAGEMENT OF GASTROINTESTINAL GVHD IN CHILDREN AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Ali, M.1, Asim, M.1, Ling, S.2, Schechter, T.1, Doyle, J.1, Gassas, A.1
1The Hospital for Sick Children, Toronto, ON, Canada; 2The Hospital
for Sick Children, Toronto, ON, Canada
Diagnostic endoscopic procedures are considered part of theman-
agement of children post haematopoietic stem cell transplant
(HSCT) when there is a clinical suspision of gastrointestinal (GI)
acute graft-versus-host disease (aGvHD). However, GI endoscopy
and biopsy in children is invasive, usually performed in main operat-
ing room under general anesthesia with the need for blood product
support in newly engrafted fragile patients. The diagnosis of GI
aGVHD is mostly made on clinical criteria based on stool volume,
ileus and bleeding. Our objective in this study was to review the ben-
efits of GI endoscopies and biopsies in the management of GI
aGVHD in children post HSCT.
From January 2000 to December 2009, 450 children underwent
allogeneic HSCT at the hospital for Sick Children in Toronto. Se-
venty-nine (17.5%) patient underwent endoscopy and GI biopsy
for suspicion of GI aGVHD. The majority were boys, . 10 years
of age with underlying haematological malignancies. Donor sources
were: Unrelated 50; related 29. Stem cell source were; BM60%, cord
25% and PBSC 15%. Themajority received meyloablative regimens
with cyclosporine and methotrexate (or methylprednisolone for
cords) for GvHD prophylaxis. All the patients engrafted within 8-
49 days. Clinical grading of GI aGVHD was, I in 5 patients, II in
39, III in 23 and grade IV in 12 patients. All patients tolerated endos-
copy and GI biopsy well except for one patient who developed duo-
denal hematoma requiring prolonged GI rest.
GI biopsy confirmed aGVHD in 49 (62%) patients and results
were negative in 30(38%) patients. Eight patients had positive viral
studies from the biopsy (adeno 5, CMV 1, HHV6 1 and EBV 1)
and one biopsy was positive for Candida. Thirty- two (40%) patients
have started treatment for GI aGvHD before the biopsy was done
based on clinical criteria, while 24/79 (30%) patients started treat-
ment after the biopsy results. Fifteen (19%) patients required 2nd
line therapy for progressive GI GvHD based on clinical non re-
sponse criteria. Twenty-nine (36%) patients died; 20 due to TRM
and GvHD complications and 9 children died because of recurrence
of their underlying malignancy.Conclusion: GI biopsy results after clinical suspicion of aGvHD in
children post allogeneic HSCT led to starting or altering therapy in
30% of the patients. Patients who were already on therapy for GI
GvHD, biopsy results did not alter their management and escalating
therapy was based on clinical progression.289
MYELO-ABLATIVE EXPOSURE OF BUSULFAN+FLUDARABINE IN
PEDIATRIC HSCT IS A SIMILARLY EFFECTIVE CONDITIONING REGIMEN
COMPARED TO BUCY4 BUT LESS TOXIC
Bartelink, I.H.1, Flinsenberg, T.W.H.2, Bierings, M.2, Egberts, T.1,
Boelens, J.J.2 1UMC Utrecht, Utrecht, Netherlands; 2UMC Utrecht,
Utrecht, Netherlands
Background: Busulfan (Bu) as myeloablative agent is used in condi-
tioning prior to HSCT mainly in combination with cyclophospho-
mide (Cy). In pediatric patients receiving BuCy4, we recently
found a clear association between busulfan-exposure and outcomes:
overall survival (OS) and event free survival (EFS). Toxicity leading
to morbidity and associated mortality remains a limiting factor in
HSCT. Comparative studies in adults showed a favorable toxicity
profile for busulfan+fludarabine (BuFlud) compared to BuCy. In
paediatrics, limited data is available regarding this regimen. BuFlud
was recently (2009) introduced in our center to replace the BuCy4
regimen for myeloid malignancies and all non-malignant indica-
tions. We compared the outcomes with our BuCy4 historic controls
transplanted between 2005-March 2009.
Methods: Fludarabine 40mg/m2 was given in 1 hour prior to a 3
hour infusion of once daily busulfan. Busulfan dose targeting, based
on therapeutic drug monitoring was performed before the second
dose. The target area under the curve (AUC) for Bu was . 74
mg*h/L (cummulative) in both groups Thymoglobuline 10mg/kg
was given in the unrelated donor setting. Primary endpoints were
EFS and OS. Secondary endpoints: acute graft-versus-host disease
(aGvHD), VOD, duration of the neutropenic period and the number
of erythrocyte and thrombocyte transfusions. A risk factor analysis
was performed using univariable and multivariable COX regression.
Results: 29 patients (19 unrelated cord blood, 8 MSD and 2 MUD)
were included in the BuFlud group (median follow up 219 days;
range 42-593) and 44 in the BuCy4 group (975 days; range 6-
1950). The groups were comparable regarding donor source, age,
gender, indication for HSCT and match-grade. EFS and OS in Bu-
Flud and BuCy was 75% vs 71% (NS) and 82% vs. 73% (NS), resp.
Probablility on neutrophile engraftment (day60) was 92% (BuCy4)
and 94% (BuFlu) No difference in aGvHD ($ grade 2) was found,
23%: BuFlu vs 30%: BuCy4. Less VODwas seen in the BuFlu group
(3% vs 18%: p5 0.012). The duration of neutropenia wasmedian 12
days in the BuFlud group compared to 20.5 days in BuCy4 (p 5
0.012). The median number of erythrocyte transfusion in BuFlu
was 1 (range 1-13) vs. 5 (0-22) in BuCy4 (p5 0.04) and thrombocyte
infusions 4 (range 0-33) vs 10 (range 2-44: p 5 0,02), resp.
Conclusions: Busulfan+fludarabine showed to be as effective but
a lesser toxic regimen than BuCy4. Further follow up and extension
of the series is needed.290
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
FOR PEDIATRIC ACUTE MYELOGENOUS LEUKEMIA (AML): MATCHED
SIBLING VS UNRELATED CORD BLOOD (UCB) DONOR
Choudhury, N.G., Duerst, R.E., Chaudhury, S., Tse, W.,
Schneiderman, J., Kletzel, M. Children’s Memorial Hospital, Chicago, IL
Indications for allogeneic HSCT in treatment of pediatric AML
have varied with changing efficacy of conventional AML regimens,
improved understanding of ‘‘high-risk’’ biology, as determined by
minimal residual disease and/or cytogenetic alterations in the leuke-
mic clone and progenitor cell sources. We report the experience of
40 children/young adult patients (pts) with primary AML undergo-
ing initial allogeneic HSCT at Children’s Memorial Hospital be-
tween January 2000 and December 2008 comparing the results of
the UCB recipients (n 5 22) with recipients of matched sibling
(msib) marrow/peripheral blood stem cells (m/PBSC, n 5 18).
